Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease

H Liu, VS Sridhar, J Boulet, A Dharia, A Khan… - Metabolism, 2022 - Elsevier
Abstract Type 2 diabetes (T2D) is one of the most common causes of chronic kidney disease
(CKD) and cardiovascular (CV) disease. Until recently, glycemic and BP control were the …
被引用次数：57 相关文章

Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease

H Liu, VS Sridhar, J Boulet, A Dharia… - Metabolism …, 2022 - pubmed.ncbi.nlm.nih.gov
Type 2 diabetes (T2D) is one of the most common causes of chronic kidney disease (CKD)
and cardiovascular (CV) disease. Until recently, glycemic and BP control were the …

Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease.

H Liu, VS Sridhar, J Boulet, A Dharia… - Metabolism: Clinical …, 2021 - europepmc.org
Type 2 diabetes (T2D) is one of the most common causes of chronic kidney disease (CKD)
and cardiovascular (CV) disease. Until recently, glycemic and BP control were the …

[引用][C] Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease

H Liu, VS Sridhar, J Boulet, A Dharia, A Khan… - Metabolism, 2022 - cir.nii.ac.jp
Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers
to clinical outcomes in heart failure and diabetic kidney disease | CiNii Research CiNii 国立 …

Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease

H Liu, V Sridhar, J Boulet, A Dharia… - Metabolism: Clinical …, 2022 - avesis.tedu.edu.tr
© 2021 Elsevier Inc. Type 2 diabetes (T2D) is one of the most common causes of chronic
kidney disease (CKD) and cardiovascular (CV) disease. Until recently, glycemic and BP …

Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease

H Liu, VS Sridhar, J Boulet, A Dharia… - Metabolism …, 2022 - metabolismjournal.com
Abstract Type 2 diabetes (T2D) is one of the most common causes of chronic kidney disease
(CKD) and cardiovascular (CV) disease. Until recently, glycemic and BP control were the …